Congressman Lou Correa (D-CA), alongside Reps. Morgan Luttrell (R-TX), Jack Bergman (R-MI), and Michael McCaul (R-TX), introduced the Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen Efficacy (IBOGAINE) Act. This legislation would codify President Donald J. Trump’s Executive Order No. 14401, which accelerates the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States.
Codify the executive order accelerating development of and access to psychedelic-assisted treatments, including ibogaine therapy, to protect veterans' access to those treatments.
Occurrences
Evidence
Review of official 119th Congress legislation records found no enacted statute, and no clear Correa-sponsored codification bill, for EO 14401 or an ibogaine/psychedelic veterans access codification as of 2026-07-10.
EO 14401 directs FDA and DEA to establish access pathways for psychedelic drugs, including ibogaine compounds, under Right to Try; directs HHS/ARPA-H to allocate at least $50 million for state partnerships; and directs HHS, FDA, and VA collaboration. It also says implementation is subject to appropriations and creates no enforceable right or benefit.
The White House described the order as accelerating research and improving access to psychedelic drugs for serious mental illness, particularly veterans. The release quoted Rep. Lou Correa saying the action is good for veterans and that psychedelics show promise for PTSD, mental health, alcoholism, drug addiction, Alzheimer’s and other ailments.
The report says Rep. Lou Correa co-founded the Congressional Psychedelics Advancing Therapies Caucus, lawmakers from both parties were working on legislation to boost the field, and Correa welcomed the Trump executive order. It also reports FDA priority vouchers for several psychedelic drugs but notes those actions do not guarantee approval.
Politico reported that Correa stood with PATH Caucus co-founder Jack Bergman and other lawmakers pressing FDA on MDMA-assisted therapy for PTSD, and that Bergman and Correa had led congressional efforts to include psychedelics provisions in VA and Defense funding bills.
Assessments
The promised outcome was statutory codification of EO 14401 to protect veterans' access to psychedelic-assisted treatments including ibogaine. The executive order itself exists and aligns with the policy goal, and Correa publicly supported it and has materially advanced related psychedelic-treatment work through the PATH Caucus and veterans-related funding efforts. But the record provided does not show an enacted federal statute, or even a clear Correa-sponsored codification bill, that codified the EO. Because the core codification promise was not delivered, but Correa made serious aligned legislative and advocacy efforts, this is a failed delivery with effort credit.